Core Viewpoint - The stock of Yaoshi Bang (09885) has seen a significant increase of over 9%, driven by strong growth in its proprietary brand business and the introduction of new medical devices aimed at grassroots healthcare institutions [1][2] Group 1: Financial Performance - Yaoshi Bang's proprietary brand business GMV grew by 115.6% year-on-year to 1.08 billion yuan in the first half of 2025, with the higher-margin self-owned brand GMV increasing by 473.4% to 852 million yuan [1] - The company has achieved a trading volume of 320 million Hong Kong dollars, reflecting strong market interest [1] Group 2: Product Development and Market Strategy - In 2024, the company plans to launch three new "Future Spectrum" series POCT devices, focusing on the grassroots healthcare market to enhance its disease detection capabilities [2] - As of June 2025, the company has covered over 18,000 terminal institutions and deployed more than 23,000 units of its POCT devices, with plans for accelerated deployment in the second half of 2025 [2] - The POCT devices will be integrated with the "Spectrum Cloud Diagnosis" SaaS system and AI-assisted systems, aiming to improve clinic management and user engagement [2] Group 3: Future Growth Potential - The company is actively advancing the application of AI and robotics technology to enhance downstream customer capabilities and optimize supply chain efficiency, which is expected to drive further growth [2]

Core Viewpoint - Tianfeng Securities maintains a "buy" rating for Yaoshi Bang (09885) and raises the forecast for net profit attributable to shareholders for 2025-2027 from 1.56/3.73/6.02 billion to 1.79/4.03/6.50 billion, driven by strong performance in platform and self-operated businesses, as well as breakthroughs in proprietary brand business [1] Group 1: Platform Business - In H1 2025, the company's platform business generated revenue of 4.36 billion, reflecting a year-on-year increase of 11.66% [1] - The company enhanced the richness of its platform business products, increasing the average monthly SKU count to approximately 4 million, significantly meeting diverse user needs [1] - The company focused on the core value extraction of traditional Chinese medicine pieces, providing 125,000 SKUs to downstream customers, a year-on-year increase of 22.5% [1] Group 2: Self-Operated Business - In H1 2025, the self-operated business achieved revenue of 93.89 billion, a year-on-year increase of 12.5% [2] - The self-operated business provided an average monthly SKU count of 480,000, an increase of 58,000 SKUs in H1 2025 [2] - The proportion of same-city orders delivered within half a day increased to 70%, while the return rate decreased to 0.4% [2] - The company strengthened the direct supply model from manufacturers, optimizing procurement channels to reduce operational costs [2] Group 3: Proprietary Brand Business - In H1 2025, the transaction scale of the proprietary brand business reached 1.08 billion, a year-on-year increase of 115.6% [3] - The proprietary brand business contributed significantly to the high-quality growth of the self-operated business, with a transaction scale of 852 million, a year-on-year increase of approximately 473.4% [3] - The major product, Le Yaoshi Huoxiang Zhengqi Oral Liquid, achieved substantial breakthroughs in coverage at grassroots medical terminals [3]

Core Viewpoint - Tianfeng Securities maintains a "buy" rating for Yaoshi Bang (09885) and raises the forecast for net profit attributable to shareholders for 2025-2027 from 1.56/3.73/6.02 billion to 1.79/4.03/6.50 billion [1] Group 1: Platform Business - In H1 2025, the company's platform business generated revenue of 436 million, reflecting a year-on-year increase of 11.66% [1] - The company has enhanced the product richness of its platform business, increasing the average monthly SKU count to approximately 4 million, significantly meeting diverse user needs [1] - The company focused on the core value extraction of traditional Chinese medicine pieces, providing 125,000 SKUs to downstream buyers, a year-on-year increase of 22.5% [1] Group 2: Self-operated Business - In H1 2025, the self-operated business achieved revenue of 9.389 billion, a year-on-year increase of 12.5% [2] - The self-operated business provided an average monthly SKU count of 480,000, an increase of 58,000 SKUs [2] - The proportion of same-city orders delivered within half a day increased to 70%, and the return rate decreased to 0.4% [2] - The company strengthened its direct supply model and optimized procurement channels to reduce operational costs [2] Group 3: Proprietary Brand Business - In H1 2025, the transaction scale of the proprietary brand business reached 1.08 billion, a year-on-year increase of 115.6% [3] - The proprietary brand contributed significantly to the high-quality growth of the self-operated business, with a transaction scale of 852 million, a year-on-year increase of approximately 473.4% [3] - The major product, Le Yaoshi Huoxiang Zhengqi Oral Liquid, achieved substantial breakthroughs in coverage at grassroots medical terminals [3]

Group 1 - The report highlights the calendar effect on market performance before and after the National Day holiday from 2010 to 2024, indicating a median return of -0.81% in the five trading days before the holiday and a strong median return of 2.27% in the first five trading days after the holiday, with an overall median increase of 2.28% over the following 20 trading days [2][28][29] - Domestic industrial profits saw a significant year-on-year increase in August, with the cumulative year-on-year growth turning positive, and marginal increases in profit margins for mining, manufacturing, and public utilities [2][30] - Internationally, the core PCE growth rate in the US for August met expectations at 2.9%, with a high probability of a 25 basis point rate cut by the Federal Reserve in October 2025 [2][31] Group 2 - The report discusses the importance of lithography machines in the semiconductor industry, emphasizing their role as the most significant category of semiconductor equipment and the continuous development opportunities driven by semiconductor demand [4][33] - The report notes that the semiconductor sector showed strong performance during the week of September 22-26, with an average daily trading volume of 23,092 billion yuan, despite a slight decrease from the previous week [4][34] - Key themes include the domestic validation of lithography machines by SMIC, the high demand for AI and robotics, and the emergence of humanoid robots marking a new era in the industry [4][34][37] Group 3 - The report outlines the "以存代算" (compute by storage) paradigm in AI storage, highlighting its significance in AI inference and the hardware breakthroughs that allow SSDs to participate as core components in AI processing [10] - The report identifies several companies actively involved in the "以存代算" space, including Huawei and Inspur, which are developing products that optimize storage architecture and cache management [10] - The report indicates that the demand for SSDs is expected to grow faster than traditional curves due to the AI storage revolution [10] Group 4 - The report discusses the potential of planetary roller screws in automotive applications, particularly in brake systems and steering systems, highlighting their advantages over traditional technologies [11] - The market share of foreign manufacturers in the planetary roller screw market exceeded 60% in 2022, with Swiss company GSA/Rollvis holding a dominant position [11] - The report anticipates a gradual increase in the market penetration of rear-wheel steering technology using planetary roller screws from 2025 to 2030 [11] Group 5 - The report emphasizes the release of the "Stabilization and Growth Work Plan for the Petrochemical Industry" by multiple ministries, which aims to optimize the industry structure and promote high-quality development [20] - The report suggests that the petrochemical sector is transitioning from a focus on expansion to optimizing existing capacities and pursuing high-quality growth opportunities [20] - The report indicates that the chemical sector is expected to benefit from price recovery cycles and the emergence of new high-end materials [20]

Summary of Key Points from the Conference Call Industry Overview - The current consumer market is expected to recover gradually, with many companies entering a bottoming phase. The liquor industry is projected to see a turning point by Q1 2026, while health foods, dairy products, and small-cap companies present significant investment opportunities [17][19] Core Insights and Arguments - **Food and Consumer Stocks**: Anticipated decline in holdings for food and consumer stocks to historical lows in Q3 2025, with active holdings expected to be very low. This trend may continue for several quarters, eventually forming a bottom [3] - **Investment Opportunities in Food Stocks**: Significant investment opportunities are expected in food stocks next year, with valuations potentially dropping below 15 times earnings and price-to-sales ratios between 1 to 3 times, especially for companies with stable revenues and strong market shares [5][12] - **Liquor and Traditional Consumer Goods**: The liquor industry may have recovery opportunities next year if Q4 reports show positive results. The traditional Chinese medicine sector, despite poor performance this year, has low valuations and strong pricing power, suggesting a faster recovery than other sectors [6][8] - **Health Food Sector**: The health food sector has performed well this year, with companies like Chengfang Bio, Baihe, Xianle, and Jindawei showing promise. The integration of pet-related businesses may further enhance growth opportunities [9][11] Noteworthy Companies and Valuations - **Yili Co., Ltd.**: Valuation is attractive, with expected price-to-sales ratios dropping to 1.5-1.7 times next year. The company has a strong cash reserve of over 50 billion to 60 billion, indicating potential for value creation during bull markets [12] - **Vitasoy International**: Notable for its low price-to-sales ratio of only 2 times and strong cash position, with revenue recovering to 5-6 billion. The company is expected to enhance profitability through management optimization [10] - **Small-Cap Companies**: Companies like Xingye Technology and Tiantie are highlighted for their governance improvements and strong technological capabilities, indicating potential for significant growth [15][16] Challenges and Market Dynamics - **Traditional Consumer Goods**: The traditional consumer sector, including liquor and Chinese medicine, faces challenges due to insufficient product innovation and economic volatility. Many companies are postponing new product launches until 2026 [2][7] - **Market Sentiment**: There is growing concern in the market regarding the performance of traditional consumer goods, particularly with the decline in prices for premium liquor brands like Moutai [2][7] Future Outlook - **Policy Support for Traditional Medicine**: The Chinese medicine sector may improve with policy support and increased capital involvement. Companies with strong cash reserves and high dividend payouts are expected to perform better [8][14] - **Investment Strategy**: The focus will remain on increasing the proportion of small-cap stocks and closely monitoring developments in food, Chinese medicine, non-alcoholic beverages, and liquor sectors [20]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6]. Core Insights - The company achieved a revenue of 9.843 billion yuan in H1 2025, representing a year-on-year increase of 11.66%. The net profit attributable to shareholders reached 78 million yuan, up 258.01%, while the net profit excluding non-recurring items soared by 1602.64% to 78 million yuan [1]. - The platform business saw a slight revenue decline to 436 million yuan in H1 2025, but the company enhanced product diversity, increasing the average monthly SKU count to approximately 4 million, significantly meeting diverse user needs [2]. - The self-operated business generated 9.389 billion yuan in revenue, a 12.5% increase year-on-year, with improvements in operational capabilities across four dimensions: product variety, delivery speed, quality, and cost efficiency [3]. - The proprietary brand business recorded a transaction scale of 1.08 billion yuan, a year-on-year increase of 115.6%, with proprietary brand transactions reaching 852 million yuan, up approximately 473.4% [4]. - Profit forecasts for 2025-2027 have been revised upwards, with net profit estimates adjusted to 179 million yuan, 403 million yuan, and 650 million yuan respectively, indicating strong growth potential [5]. Summary by Sections Financial Performance - In H1 2025, the company reported a total revenue of 9.843 billion yuan, with a significant increase in net profit and cash flow, indicating robust financial health [1]. Platform Business - The platform business experienced a slight revenue decline but improved product offerings, focusing on traditional Chinese medicine with a notable increase in SKU count [2]. Self-Operated Business - The self-operated segment showed strong revenue growth, with enhancements in delivery efficiency and product quality, contributing to overall operational improvements [3]. Proprietary Brand Business - The proprietary brand initiative has become a key growth driver, with substantial increases in transaction volumes, showcasing the effectiveness of the brand strategy [4]. Profit Forecasts - The upward revision of profit forecasts reflects confidence in the company's growth trajectory, supported by strong performance in both platform and self-operated businesses [5].

藥師幫股份有限公司 YSB Inc. （於開曼群島註冊成立的有限公司） 股份代號：9885 2025 中期報告 INTERIM REPORT 2025 中期報告 目錄 2 公司資料 4 業務回顧與展望 13 財務摘要 14 管理層討論及分析 21 企業管治及其他資料 32 簡明綜合財務報表審閱報告 33 簡明綜合損益及其他全面收益表 34 簡明綜合財務狀況表 36 簡明綜合權益變動表 37 簡明綜合現金流量表 38 簡明綜合財務報表附註 58 釋義 公司資料 非執行董事 朱梓陽先生 獨立非執行董事 邵蓉女士 孫含暉先生 趙宏強先生 審計委員會 趙宏強先生 （主席） 邵蓉女士 孫含暉先生 薪酬委員會 董事會 執行董事 張步鎮先生 （主席兼首席執行官） 陳飛先生 孫含暉先生 （主席） 邵蓉女士 趙宏強先生 提名委員會 張步鎮先生 （主席） 邵蓉女士 孫含暉先生 趙宏強先生 環境、社會及企業管治委員會 趙宏強先生 （主席） 邵蓉女士 孫含暉先生 聯席公司秘書 陳飛先生 馮慧森女士 授權代表 陳飛先生 馮慧森女士 審計師 德勤 • 關黃陳方會計師行 執業會計師 註冊公眾利益實體核數師 香港銅鑼灣 希慎道33號 利園一 ...

Group 1: Financial Market Developments - The Hong Kong stock market is experiencing significant growth, with the Hang Seng Index rising over 20% since the beginning of the year and daily average trading volume approaching HKD 250 billion, nearly doubling from last year [3][4] - The IPO fundraising amount has reached over HKD 130 billion by the end of August, marking a nearly sixfold year-on-year increase, making Hong Kong the top global market for IPOs [3][4] - The government aims to assist Chinese concept stocks in returning to Hong Kong as their preferred listing location, with potential for 27 Chinese concept stocks to return, representing a total market value exceeding HKD 1.4 trillion [5][6] Group 2: Regulatory and Structural Reforms - The Chief Executive's policy address includes plans to optimize the main board listing and issuance mechanisms, explore shortening the stock settlement cycle to T+1, and promote more overseas companies to list in Hong Kong [4][6] - The introduction of the "Tech Company Fast Track" aims to facilitate the listing of technology and biotech companies, allowing them to submit applications confidentially [4][6] Group 3: International Gold Trading Market - The Hong Kong government is accelerating the establishment of an international gold trading market, with a target to exceed 2,000 tons of gold storage within three years [7][8] - Measures include building a central clearing system for gold transactions and enhancing collaboration with the Shanghai Gold Exchange to prepare for future connectivity with the mainland market [7][8] - The demand for gold is expected to remain strong due to geopolitical uncertainties, positioning Hong Kong as a key player in the global gold market [8]

Core Viewpoint - CITIC Securities initiates coverage on Yaoshi Bang (9885.HK) with a "Buy" rating, highlighting its strong profitability and growth prospects [1] Group 1: Financial Performance - Yaoshi Bang's revenue is projected to grow from 6.06 billion to 17.904 billion from 2020 to 2024, with a compound annual growth rate (CAGR) of 31.1% [1] - The company is expected to achieve revenue and net profit attributable to shareholders of 9.843 billion and 78 million respectively in the first half of 2025, representing year-on-year growth of 11.7% and 258% [1] - Forecasted net profits for 2025-2027 are 148 million, 315 million, and 512 million, with year-on-year growth rates of 393.6%, 112.3%, and 62.7% respectively [1] Group 2: Business Strategy and Market Position - Yaoshi Bang is focusing on the outpatient sinking market, enhancing its self-operated brand and proprietary brand business, which are driving revenue and gross margin improvements [1] - The company is expected to benefit from the steady growth of POCT (Point of Care Testing) devices, achieving synergy among medicine, pharmacy, and testing [1] - Multiple brokerages, including Xinda Securities and Great Wall Securities, maintain a positive outlook on Yaoshi Bang, citing strong growth from its proprietary brand business and a strategic shift from "scale expansion" to "profit enhancement" [2] Group 3: Stock Performance and Market Sentiment - Yaoshi Bang's stock price has increased from 5 HKD to around 11 HKD this year, with a maximum increase of over 120% [2] - The stock is currently stabilizing around 10 HKD, with analysts suggesting that the company is in a phase of shareholder chip exchange, leading to potential short-term volatility [2] - The company's fundamentals are strong, and after completing the chip exchange and stabilizing, there may be opportunities for upward breakthroughs [2]

Core Insights - The company achieved significant revenue growth of 27.1% year-on-year in H1 2025, reaching RMB 153 million, while net losses narrowed to RMB 41 million from RMB 60 million in the same period last year [1] - The growth was primarily driven by a substantial increase in revenue from six-axis collaborative robots, which accounted for 61.2% of total revenue [1] - The company has made key advancements in embodied intelligence, with the humanoid robot DOBOT Atom set to begin global mass production in June 2025 [1] Revenue and Profitability - The gross margin for H1 2025 was 47.0%, an increase of 3.1 percentage points year-on-year, while the adjusted gross margin remained stable at 49.4% [2] - The net loss margin improved to 26.7% from 49.7% in the previous year, indicating better operational efficiency [2] - Total operating expenses decreased to 99.4% from 109.3% year-on-year, with significant reductions in management expenses due to the absence of listing costs [2] Research and Development - R&D expenditure increased by 30.3% year-on-year to RMB 41 million, reflecting the company's commitment to advancing key technologies, particularly in humanoid robotics [2] - Sales expenses also rose by 31.5%, aimed at enhancing global sales channel expansion [2] Strategic Partnerships - The company signed a strategic cooperation agreement with Yaoshi Bang on June 3, 2025, to explore smart solutions in the pharmaceutical industry, integrating robotics technology with pharmaceutical applications [2] Future Outlook - Revenue forecasts for the company are projected at RMB 500 million, RMB 670 million, and RMB 900 million for 2025-2027, with current market valuations corresponding to price-to-sales ratios of 40, 30, and 23 times respectively [3]